



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

20 Feb 2017 (#8)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date. The application will be submitted two (2) days before the application due date.**

Important notices

- Update on Clinical Trial Funding Opportunity Announcement Policy ([NOT-OD-17-043](#))
- Impact of Washington, DC Area Federal Office Operating Status on AHRQ Grant Application Due Dates ([NOT-HS-17-007](#))

1. Human Heredity and Health in Africa (H3Africa) call for proposals for collaborative research projects from the Alliance for Accelerating Excellence in Science in Africa (AESA), with support from Wellcome Trust.

Hyperlink: [H3Africa](#)

Type: research consortium

Application Due Date: 1st Stage 24 March 2017. Preliminary application forms should be submitted by 24th March 2017 through the [Ishango Online Application Portal](#). The preliminary application will ask applicants to provide:

- A brief summary of their proposed project (200 words)
- The high-level aims and objectives of the network, the scientific questions/hypotheses it will address, and how they relate to the vision of H3Africa (750 words)
- The approaches that will be used to achieve the objectives, including high-level targets, expected outcomes and role of each co-applicant (750 words)
- An outline of the proposed management and governance arrangements for the network (300 words)
- A description of the strategy for community engagement and ethical challenges posed by this research and whether the applicants envisage any multidisciplinary research to inform best practice with respect to ethical, legal and social issues (500 words)
- An indication of the level of support requested by each institution in the network
- CVs of the principal applicant and all co-applicants
- A list of major collaborators and their institutions.

Invitations for full applications will be sent out by 26th April 2017. invited to submit a full application, applicants should complete and submit this online to AESA by 23:59 GMT on 14th July 2017. A webinar for potential applicants will be held on the 9th March 2017, but if you have questions in advance of the webinar, please contact: H3Africa@aasciences.ac.ke.

This Funding Opportunity Announcement (FOA) Wellcome has made a £9m grant to AESA to run a second phase of the programme in partnership with the US National Institutes of Health. (NIH). The NIH will manage their awards, while AESA will be responsible for the delivery of the Wellcome Trust component of Phase II awards for the H3Africa initiative and will manage the H3Africa consortium in partnership with the Wellcome Trust and the NIH. In addition, AESA has entered into a collaboration with GlaxoSmithKline (GSK) as part of the Africa NCD Open Lab initiative, where additional funding will be made available to fund projects aligned to the Open Lab's objectives. H3Africa is organised as a research consortium that brings participants together in a highly collaborative and synergistic effort. The H3Africa Consortium includes all participants of research and infrastructure projects funded through H3Africa, as well as responsible Wellcome Trust and NIH staff.

The scientific scope of applications responsive to this FOA should be broadly focused on using genomics and other cutting-edge approaches to understand how human genetic variation combined with environmental risk factors affect specific disease outcomes, exposures to specific disease, or impact other specific health-related traits in Africa. It is envisaged that studies funded through the initiative will inform subsequent strategies to address the health inequities in both non-communicable (NCDs) and communicable diseases (CDs), leading to new approaches for public health benefits such as the use of precision medicine for Africans.

The scope for NCDs may include but is not limited to cancer, chronic kidney disease, diabetes mellitus, cardiovascular disease, mental illness, neurological disorders, and others. Research involving communicable diseases, including HIV/AIDS, malaria, tuberculosis, leishmaniasis, trypanosomiasis, schistosomiasis, ebola, lassa fever, and others of significant public health importance in Africa will be considered. Applications that explore the link between infectious disease and NCDs will also be considered.

Budget: Awards can be up to a maximum of £2.5 million, but projects smaller in scope from emerging African scientists are encouraged. Projects can be up to 4 years in duration and can include the following: Support for staff, Materials and consumables, Equipment purchase and maintenance, Community engagement, Travel, training and network meetings.

2. Oral HIV Vaccination: Strategy Synergistic to Systemic Vaccination

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-DE-18-008\)](#)

Type: R01

Application Due Date: November 24, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) encourages hypothesis driven basic, translational and pre-clinical science research to develop novel approaches for prophylactic oral mucosal vaccine that will be synergistic with systemic vaccination for protection against HIV infection.

Budget: NIDCR intends to fund an estimate of 3-4 awards, corresponding to a total of \$2 million, for fiscal year 2018. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

3. National Institute of Mental Health: Formative and Pilot Intervention Research for Prevention and Treatment of HIV/AIDS

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PA-17-166\)](#)

Type: R34

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, "intervention" is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.

Budget: Direct costs are limited to \$450,000 over the entire project period, with no more than \$225,000 in direct costs in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed three years.

4. Research To Address Sleep Disorders in the Context of Medical Rehabilitation

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-163\)](#)

Type: R01

Application Due Date: April 21, 2017, March 30, 2018, March 29, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) Patients with many disabilities report problems sleeping, but specific sleep disorders are often not diagnosed. Because sleep affects many physiological and behavioral parameters--depression, anxiety, pain, cancer, cardiovascular changes, immune function-- sleep disorders should be diagnosed and appropriately treated to maximize benefit of rehabilitation. Research is needed on ways to best approach this complexity in the context of medical rehabilitation for a primary, non-sleep disorder.

Budget: Application budgets are limited \$499,999 or less direct costs per FY and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Early Phase Clinical Trials in Imaging and Image-Guided Interventions National Cancer Institute

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-17-167\)](#)

Type: R01

Application Due Date: June 28, 2017; October 11, 2017; February 14, 2018, June 28, 2018; October 11, 2018; February 14, 2019; June 28, 2019; October 11, 2019; February 14, 2020. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. *Applicants should be aware that on-time submission means that an application is submitted error free* (to both Grants.gov and eRA Commons) on the application due date.

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPoREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Budget: Application budget should reflect the actual needs of the proposed project and is limited to \$500,000 in direct costs for the total project period. No more than \$250,000 in direct costs may be requested in any single year. The total project period may not exceed 3 years

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements (*click on “PA” to search for further funding opportunities*)

RFA Request for Applications (*click on “RFA” to search for further funding opportunities*)

Complete [Glossary and acronym list of NIH Terms](#)

